Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
IRVINE, Calif., Aug. 11, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against MAXIMUS, Inc. (“MAXIMUS” or the “Company”) (NYSE:MMS). Investors who purchased or otherwise acquired shares between October 30, 2014 and February 3, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 6, 2017 lead plaintiff motion deadline.
If you purchased MAXIMUS shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, MAXIMUS made false and/or misleading statements and/or failed to disclose that: in obtaining the Health Assessment Advisory Service (“HAAS”) contract, the Company set an unattainable target number of healthcare professionals to recruit and an unattainable target number of assessments; that throughout the HAAS contract, MAXIMUS was struggling to recruit, train and ramp-up new health care staff to perform the assessments; that the inability to meet its target number of healthcare recruits and target number of assessments, meant MAXIMUS would not earn the performance-based incentive fees from the HAAS contract; and that as a result, the Company’s statements about its financial condition and business outlook, including statements about the HAAS contract and the amount of revenue MAXIMUS expected the contract to contribute, lacked a reasonable basis when made. When this information was announced, shares of MAXIMUS decreased in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
